Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression

OncoImmunology

Volumn 5, Issue 11, 2016, Pages

  Chen, Limo ^a   Yi, Xiaohui ^a   Goswami, Sangeeta ^a   Ahn, Young Ho ^a,b   Roybal, Jonathon D ^a   Yang, Yongbin ^a,c   Diao, Lixia ^a   Peng, Di ^d,e   Peng, David ^a   Fradette, Jared J ^a   Wang, Jing ^a   Byers, Lauren A ^a   Kurie, Jonathan M ^a   Ullrich, Stephen E ^a   Qin, F Xiao Feng ^a,d,e   Gibbons, Don L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ewha Womans University School of Medicine   (South Korea)

^c SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^d INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^e SUZHOU INSTITUTE OF SYSTEMS MEDICINE   (China)

Author keywords

BMP4; EMT; immunotherapy; lung cancer; miR 200; PD L1

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; K RAS PROTEIN; MICRORNA 200; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; COCULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; LUNG ADENOCARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; T CELL DEPLETION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84994662297     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1234570     Document Type: Article

References (58)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; doi:10.1038/nature01322
2. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37; PMID:16397525; doi:10.1038/nrc1782
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; doi:10.1016/j.cell.2010.01.025
4. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-52; doi:10.1038/nrc2618
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:19279573; doi:10.1038/nature07205
6. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; doi:10.1126/science.1129139
7. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; doi:10.1056/NEJMoa051424
8. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104:3967-72; PMID:17360461; doi:10.1073/pnas.0611618104
9. Zhuang X, Xia X, Wang C, Gao F, Shan N, Zhang L, Zhang L. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010; 18:24-8; PMID:19713832; doi:10.1097/PAI.0b013e3181b6a741
10. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; doi:10.1146/annurev.immunol.22.012703.104803
11. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19:72-85; PMID:21251614; doi:10.1016/j.ccr.2010.11.011
12. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; doi:10.1038/nrc1586
13. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5:5241; PMID:25348003; doi:10.1038/ncomms6241
14. Chen L, Heymach JV, Qin FX, Gibbons DL. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunol 2015; 4:e1002731; PMID:26155392; doi:10.1080/2162402X.2014.1002731
15. Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest 2012; 122:3170-83; PMID:22850877; doi:10.1172/JCI63608
16. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, et al. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 2014; 124:2696-708; PMID:24762440; doi:10.1172/JCI72171
17. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 2011; 121:1373-85; PMID:21403400; doi:10.1172/JCI42579
18. Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. The microRNA-200/Zeb1 axis regulates ECM-dependent beta1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep 2016; 6:18652; PMID:26728244; doi:10.1038/srep18652
19. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23:2140-51; PMID:19759262; doi:10.1101/gad.1820209
20. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, et al. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PloS One 2009; 4:e5401; PMID:14744438; doi:10.1371/journal.pone.0005401
21. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 2013; 73:571-82; PMID:23149918; doi:10.1158/0008-5472.CAN-12-0263
22. Bartel DP. MicroRNAs:genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97, [pii]; PMID:14744438; doi:10.1016/S0092-8674(04)00045-5
23. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68:7846-54; PMID:18829540; doi:10.1158/0008-5472.CAN-08-1942
24. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601; PMID:18376396; doi:10.1038/ncb1722
25. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, et al. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 2011; 71:7670-82; PMID:21987723; doi:10.1158/0008-5472.CAN-11-0964
26. Kim JS, Kurie JM, Ahn YH. BMP4 depletion by miR-200 inhibits tumorigenesis and metastasis of lung adenocarcinoma cells. Mol Cancer 2015; 14:173; PMID:26395571; doi:10.1186/s12943-015-0441-y
27. Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM, Hessmann E, Gaedcke J, Güthle M, Zenke M, et al. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun 2015; 6:7677; PMID:26497898; doi:10.1038/ncomms8677
28. Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res 2014; 74:5091-102; PMID:25224959; doi:10.1158/0008-5472.CAN-13-3171
29. Weaver M, Dunn NR, Hogan BL. Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis. Development 2000; 127:2695-704; PMID:10821767
30. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 2005; 102:419-24; PMID:15623559; doi:10.1073/pnas.0408197102
31. Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, et al. Blockade of transforming growth factor-{β} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther 2006; 5:1733-43; PMID:16891459; doi:10.1158/1535-7163.MCT-06-0109
32. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3:1011-22; PMID:15573100; doi:10.1038/nrd1580
33. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 2008; 22:191-205; PMID:18328989; doi:10.1016/j.berh.2007.11.007
34. Rajan P, Panchision DM, Newell LF, McKay RD. BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol 2003; 161:911-21; PMID:12796477; doi:10.1083/jcb.200211021
35. Wolfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, Dalpke AH, Heeg K. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413-24; PMID:21268011; doi:10.1002/eji.201040979
36. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7; PMID:16382236; doi:10.1038/nature04444
37. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-42; PMID:23470321; doi:10.1038/nri3405
38. Zinselmeyer BH, Heydari S, Sacristán C, Nayak D, Cammer M, Herz J, Cheng X, Davis SJ, Dustin ML, McGavern DB. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013; 210:757-74; PMID:23530125; doi:10.1084/jem.20121416
39. Horne-Debets JM, Faleiro R, Karunarathne DS, Liu XQ, Lineburg KE, Poh CM, Grotenbreg GM, Hill GR, MacDonald KP, Good MF, et al. PD-1 dependent exhaustion of CD8(+) T cells drives chronic malaria. Cell Rep 2013; 5:1204-13; PMID:24316071; doi:10.1016/j.celrep.2013.11.002
40. Curran MA, Montalvo W, Yagita H, Allison J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. P Natl Acad Sci USA 2010; 107:4275-80; PMID:20160101; doi:10.1073/pnas.0915174107
41. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520:373-7; PMID:25754329; doi:10.1038/nature14292
42. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer:links to genetic instability. Carcinogenesis 2009; 30:1073-81; PMID:19468060; doi:10.1093/carcin/bgp127
43. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 2016; 22:3630-42; PMID:26851185; doi:10.1158/1078-0432.CCR-15-1434
44. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, PAN-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 2016; 22:609-20; PMID:26420858; doi:10.1158/1078-0432.CCR-15-0876
45. Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 2011; 71:5194-203; PMID:21670081; doi:10.1158/0008-5472.CAN-10-4374
46. Kallioniemi A. Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior. Cancer Genet 2012; 205:267-77; PMID:22749032; doi:10.1016/j.cancergen.2012.05.009
47. Alarmo EL, Huhtala H, Korhonen T, Pylkkänen L, Holli K, Kuukasjärvi T, Parkkila S, Kallioniemi A. Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. Mod Pathol 2013; 26:10-21; PMID:22899288; doi:10.1038/modpathol.2012.128
48. Richter A, Valdimarsdottir L, Hrafnkelsdottir HE, Runarsson JF, Omarsdottir AR, Ward-van Oostwaard D, Mummery C, Valdimarsdottir G. BMP4 promotes EMT and mesodermal commitment in human embryonic stem cells via SLUG and MSX2. Stem Cells 2014; 32:636-48; PMID:24549638; doi:10.1002/stem.1592
49. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444:761-5; PMID:17151667; doi:10.1038/nature05349
50. Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 2009; 30:238-48; PMID:19056927; doi:10.1093/carcin/bgn274
51. Ye X, Weinberg RA. Epithelial-mesenchymal plasticity:a central regulator of cancer progression. Trends Cell Biol 2015; 25:675-86; PMID:26437589; doi:10.1016/j.tcb.2015.07.012
52. Okazaki T, Honjo T. PD-1 and PD-1 ligands:from discovery to clinical application. Int Immunol 2007; 19:813-24; PMID:17606980; doi:10.1093/intimm/dxm057
53. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013; 23:406-20; PMID:23453624; doi:10.1016/j.ccr.2013.01.023
54. Di Piazza M, Nowell CS, Koch U, Durham AD, Radtke F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell 2012; 22:479-93; PMID:23079658; doi:10.1016/j.ccr.2012.08.016
55. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-37; PMID:23079654; doi:10.1016/j.ccr.2012.08.024
56. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-21; PMID:3489291; doi:10.1126/science.3489291
57. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45; PMID:11328886; doi:10.1093/nar/29.9.e45
58. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511:543-50; PMID:25079552; doi:10.1038/nature13385